Effects of xenobiotics on CYP1 enzyme-mediated biotransformation and bioactivation of estradiol

References

• Abd El-Aty AM, Shah SS, Kim BM, Choi JH, Cho HJ, Hee Y, Chang BJ, Shin HC, Lee KB, Shimoda M, et al. 2008. In vitro inhibitory potential of decursin and decursinol angelate on the catalytic activity of cytochrome P-450 1A1/2, 2D15, and 3A12 isoforms in canine hepatic microsomes. Arch Pharm Res. 31(11):1425–1435.
   PubMed Web of Science ®Google Scholar
• Agostinelli E, Seiler N. 2006. Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids. 31(3):341–355.
   PubMed Web of Science ®Google Scholar
• Aimova D, Poljakova J, Kotrbova V, Moserova M, Frei E, Arlt VM, Stiborova M. 2008. Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2. Interdiscip Toxicol. 1(2):160–168.
   PubMedGoogle Scholar
• Aimová D, Stiborová M. 2005. Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 149(2):437–440.
   PubMedGoogle Scholar
• Aimova D, Svobodova L, Kotrbova V, Mrazova B, Hodek P, Hudecek J, Vaclavikova R, Frei E, Stiborova M. 2007. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos. 35(10):1926–1934.
   PubMed Web of Science ®Google Scholar
• Akinwumi BC, Bordun KM, Anderson HD. 2018. Biological activities of stilbenoids. Int J Mol Sci. 19(3):792.
   PubMed Web of Science ®Google Scholar
• Al-Dhfyan A, Alhoshani A, Korashy HM. 2017. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-catenin and Akt activation. Mol Cancer. 16(1):14.
   PubMed Web of Science ®Google Scholar
• Aldawsari FS, Elshenawy OH, El Gendy MA, Aguayo-Ortiz R, Baksh S, El-Kadi AO, Velazquez-Martinez CA. 2015. Design and synthesis of resveratrol-salicylate hybrid derivatives as CYP1A1 inhibitors. J Enzyme Inhib Med Chem. 30(6):884–895.
   PubMed Web of Science ®Google Scholar
• An D, Song Z, Yi Y, Zhang Q, Liu J, Zhang Y, Zhou J, Zhao G, Cong D, Li N, et al. 2019. Oroxylin A, a methylated metabolite of baicalein, exhibits a stronger inhibitory effect than baicalein on the CYP1B1-mediated carcinogenic estradiol metabolite formation. Phytother Res. 33(4):1033–1043.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Li N, Arroo RR. 2009. The methoxylated flavones eupatorin and cirsiliol induce CYP1 enzyme expression in MCF7 cells. J Nat Prod. 72(8):1390–1394.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Papakyriakou A, Vourloumis D, Spandidos DA. 2011. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorg Med Chem. 19(9):2842–2849.
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Papakyriakou A, Vourloumis D, Tsatsakis AM, Spandidos DA. 2010. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther. 126(1):9–20.
   PubMed Web of Science ®Google Scholar
• Annunziata F, Pinna C, Dallavalle S, Tamborini L, Pinto A. 2020. An overview of coumarin as a versatile and readily accessible scaffold with broad-ranging biological activities. Int J Mol Sci. 21(13):4618.
   PubMed Web of Science ®Google Scholar
• Badawi AF, Cavalieri EL, Rogan EG. 2000. Effect of chlorinated hydrocarbons on expression of cytochrome P450 1A1, 1A2 and 1B1 and 2- and 4-hydroxylation of 17β-estradiol in female Sprague-Dawley rats. Carcinogenesis. 21(8):1593–1599.
   PubMed Web of Science ®Google Scholar
• Baumgart A, Schmidt M, Schmitz HJ, Schrenk D. 2005. Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes. Biochem Pharmacol. 69(4):657–667.
   PubMed Web of Science ®Google Scholar
• Beedanagari SR, Bebenek I, Bui P, Hankinson O. 2009. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol Sci. 110(1):61–67.
   PubMed Web of Science ®Google Scholar
• Bertonazzi A, Nelson B, Salvador J, Umland E. 2015. The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis. Womens Health. 11(6):815–824.
   Google Scholar
• Bhattacharyya SS, Paul S, Dutta S, Boujedaini N, Khuda-Bukhsh AR. 2010. Anti-oncogenic potentials of a plant coumarin (7-hydroxy-6-methoxy coumarin) against 7,12-dimethylbenz[a]anthracene-induced skin papilloma in mice: the possible role of several key signal proteins. Zhong Xi Yi Jie He Xue Bao. 8(7):645–654.
   PubMedGoogle Scholar
• Blackburn HL, Ellsworth DL, Shriver CD, Ellsworth RE. 2015. Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy. Cancer Causes Control. 26(3):319–332.
   PubMed Web of Science ®Google Scholar
• Cai Y, Baer-Dubowska W, Ashwood-Smith M, Digiovanni J. 1997. Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured mouse keratinocytes. Carcinogenesis. 18(1):215–222.
   PubMed Web of Science ®Google Scholar
• Cai Y, Baer-Dubowska W, Ashwood-Smith MJ, Ceska O, Tachibana S, Digiovanni J. 1996. Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem Res Toxicol. 9(4):729–736.
   PubMed Web of Science ®Google Scholar
• Cai Y, Bennett D, Nair RV, Ceska O, Ashwood-Smith MJ, Digiovanni J. 1993. Inhibition and inactivation of murine hepatic ethoxy- and pentoxyresorufin O-dealkylase by naturally occurring coumarins. Chem Res Toxicol. 6(6):872–879.
   PubMed Web of Science ®Google Scholar
• Calaf GM, Ponce-Cusi R, Aguayo F, Munoz JP, Bleak TC. 2020. Endocrine disruptors from the environment affecting breast cancer. Oncol Lett. 20(1):19–32.
   PubMed Web of Science ®Google Scholar
• Chang TK, Lee WB, Ko HH. 2000. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can J Physiol Pharmacol. 78(11):874–881.
   PubMed Web of Science ®Google Scholar
• Chang YP, Huang CC, Shen CC, Tsai KC, Ueng YF. 2015. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab Pharmacokinet. 30(5):374–383.
   PubMed Web of Science ®Google Scholar
• Chatuphonprasert W, Kondo S, Jarukamjorn K, Kawasaki Y, Sakuma T, Nemoto NJB, Bulletin P. 2010. Potent modification of inducible CYP1A1 expression by flavonoids. Biol Pharm Bull. 33(10):1698–1703.
   PubMed Web of Science ®Google Scholar
• Chatuphonprasert W, Sangkawat T, Nemoto N, Jarukamjorn K. 2011. Suppression of beta-naphthoflavone induced CYP1A expression and lipid-peroxidation by berberine. Fitoterapia. 82(6):889–895.
   PubMed Web of Science ®Google Scholar
• Chaudhary A, Willett KL. 2006. Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John’s wort. Toxicology. 217(2–3):194–205.
   PubMed Web of Science ®Google Scholar
• Chen HS, Chiang PH, Wang YC, Kao MC, Shieh TH, Tsai CF, Tsai EM. 2012. Benzyl butyl phthalate induces necrosis by AhR mediation of CYP1B1 expression in human granulosa cells. Reprod Toxicol. 33(1):67–75.
   PubMed Web of Science ®Google Scholar
• Chen ST, Chen DR, Fang JP, Lin PH. 2015. 2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates estradiol-induced aldehydic DNA lesions in human breast cancer cells through alteration of CYP1A1 and CYP1B1 expression. Breast Cancer. 22(3):269–279.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Hurh YJ, Na HK, Kim JH, Chun YJ, Kim DH, Kang KS, Cho MH, Surh YJ. 2004. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis. 25(10):2005–2013.
   PubMed Web of Science ®Google Scholar
• Cheung CY, Chen J, Chang TK. 2004. Evaluation of a real-time polymerase chain reaction method for the quantification of CYP1B1 gene expression in MCF-7 human breast carcinoma cells. J Pharmacol Toxicol Methods. 49(2):97–104.
   PubMedGoogle Scholar
• Cho TM, Rose RL, Hodgson E. 2007. The effect of chlorpyrifos-oxon and other xenobiotics on the human cytochrome P450-dependent metabolism of naphthalene and deet. Drug Metabol Drug Interact. 22(4):235–262.
   PubMedGoogle Scholar
• Choi JM, Oh SJ, Lee SY, Im JH, Oh JM, Ryu CS, Kwak HC, Lee JY, Kang KW, Kim SK. 2015. HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics. Arch Pharm Res. 38(5):691–704.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Kim MY, Guengerich FP. 1999. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun. 262(1):20–24.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Kim S. 2003. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents. Med Res Rev. 23(6):657–668.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP. 2001. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61(22):8164–8170.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Lee SK, Kim MY. 2005. Modulation of human cytochrome P450 1B1 expression by 2,4,3′,5′-tetramethoxystilbene. Drug Metab Dispos. 33(12):1771–1776.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Oh YK, Kim BJ, Kim D, Kim SS, Choi HK, Kim MY. 2009. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Toxicol Lett. 189(1):84–89.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Ryu SY, Jeong TC, Kim MY. 2001. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab Dispos. 29(4 Pt 1):389–393.
   PubMed Web of Science ®Google Scholar
• Ciolino H, Yeh G. 1999. The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br J Cancer. 79(9–10):1340–1346.
   PubMed Web of Science ®Google Scholar
• Corcoran JJ, Nicholson C, Sweeney M, Charnock JC, Robson SC, Westwood M, Taggart MJ. 2014. Human uterine and placental arteries exhibit tissue-specific acute responses to 17beta-estradiol and estrogen-receptor-specific agonists. Mol Hum Reprod. 20(5):433–441.
   PubMed Web of Science ®Google Scholar
• Cui J, Li S. 2014. Inhibitors and prodrugs targeting CYP1: a novel approach in cancer prevention and therapy. Curr Med Chem. 21(5):519–552.
   PubMed Web of Science ®Google Scholar
• Cui J, Meng Q, Zhang X, Cui Q, Zhou W, Li S. 2015. Design and synthesis of new alpha-naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression. J Med Chem. 58(8):3534–3547.
   PubMed Web of Science ®Google Scholar
• Dai ZR, Feng L, Jin Q, Cheng H, Li Y, Ning J, Yu Y, Ge GB, Cui JN, Yang L. 2017. A practical strategy to design and develop an isoform-specific fluorescent probe for a target enzyme: CYP1A1 as a case study. Chem Sci. 8(4):2795–2803.
   PubMed Web of Science ®Google Scholar
• Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey JV Jr., Cauley JA, Hue TF, Lacroix A, Falk RT, Pfeiffer RM, et al. 2014. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B ∼ FIT. Carcinogenesis. 35(2):346–355.
   PubMed Web of Science ®Google Scholar
• Deeni YY, Ibbotson SH, Woods JA, Wolf CR, Smith G. 2013. Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLOS One. 8(9):e75494.
   PubMed Web of Science ®Google Scholar
• Don MJ, Lewis DFV, Wang SY, Tsai MW, Ueng YF. 2003. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. Bioorg Med Chem Lett. 13(15):2535–2538.
   PubMed Web of Science ®Google Scholar
• Dong J, Huang G, Cui Q, Meng Q, Li S, Cui J. 2021. Discovery of heterocycle-containing alpha-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors. Eur J Med Chem. 209:112895.
   PubMed Web of Science ®Google Scholar
• Dong J, Wang Z, Cui J, Meng Q, Li S. 2020. Synthesis and structure-activity relationship studies of alpha-naphthoflavone derivatives as CYP1B1 inhibitors. Eur J Med Chem. 187:111938.
   PubMed Web of Science ®Google Scholar
• Dong J, Wang Z, Meng Q, Zhang Q, Huang G, Cui J, Li S. 2018. Development of 2-arylbenzo[h]quinolone analogs as selective CYP1B1 inhibitors. RSC Adv. 8(27):15009–15020.
   PubMed Web of Science ®Google Scholar
• Dong J, Zhang Q, Cui Q, Huang G, Pan X, Li S. 2016. Flavonoids and naphthoflavonoids: wider roles in the modulation of cytochrome P450 family 1 enzymes. Chem Med Chem. 11(19):2102–2118.
   Web of Science ®Google Scholar
• Dumont J, Josse R, Lambert C, Antherieu S, Laurent V, Loyer P, Robin MA, Guillouzo A. 2010. Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines. Toxicol Appl Pharmacol. 249(1):91–100.
   PubMed Web of Science ®Google Scholar
• Dumont J, Josse R, Lambert C, Antherieu S, Le Hegarat L, Aninat C, Robin MA, Guguen-Guillouzo C, Guillouzo A. 2010. Differential toxicity of heterocyclic aromatic amines and their mixture in metabolically competent HepaRG cells. Toxicol Appl Pharmacol. 245(2):256–263.
   PubMed Web of Science ®Google Scholar
• Dunlap TL, Howell CE, Mukand N, Chen SN, Pauli GF, Dietz BM, Bolton JL. 2017. Red clover aryl hydrocarbon receptor (AhR) and estrogen receptor (ER) agonists enhance genotoxic estrogen metabolism. Chem Res Toxicol. 30(11):2084–2092.
   PubMed Web of Science ®Google Scholar
• Dvořák Z, Sovadinová I, Bláha L, Giesy JP, Ulrichová J. 2006. Quaternary benzo[c]phenathridine alkaloids sanguinarine and chelerythrine do not affect transcriptional activity of aryl hydrocarbon receptor: analyses in rat hepatoma cell line H4IIE.luc. Food Chem Toxicol. 44(9):1466–1473.
   PubMed Web of Science ®Google Scholar
• Einem Lindeman T, Poirier MC, Divi RL. 2011. The resveratrol analogue, 2,3′,4,5′-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene. Mutagenesis. 26(5):629–635.
   PubMed Web of Science ®Google Scholar
• Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, Gierach GL. 2013. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res. 15(2):R34.
   PubMed Web of Science ®Google Scholar
• Gao M, Zheng A, Chen L, Dang F, Liu X, Gao J. 2022. Benzo(a)pyrene affects proliferation with reference to metabolic genes and ROS/HIF-1alpha/HO-1 signaling in A549 and MCF-7 cancer cells. Drug Chem Toxicol. 45(2):741–749.
   PubMed Web of Science ®Google Scholar
• Ge L, Cui Y, Cheng K, Han J. 2018. Isopsoralen enhanced osteogenesis by targeting AhR/ERalpha. Molecules. 23(10):2600.
   PubMed Web of Science ®Google Scholar
• Girennavar B, Poulose SM, Jayaprakasha GK, Bhat NG, Patil BS. 2006. Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes. Bioorg Med Chem. 14(8):2606–2612.
   PubMed Web of Science ®Google Scholar
• Go RE, Hwang KA, Choi KC. 2015. Cytochrome P450 1 family and cancers. J Steroid Biochem Mol Biol. 147:24–30.
   PubMed Web of Science ®Google Scholar
• Han EH, Kim HG, Im JH, Jeong TC, Jeong HG. 2009. Up-regulation of CYP1A1 by rutaecarpine is dependent on aryl hydrocarbon receptor and calcium. Toxicology. 266(1–3):38–47.
   PubMed Web of Science ®Google Scholar
• Haque MW, Pattanayak SP. 2018. Taxifolin inhibits 7,12-dimethylbenz(a)anthracene-induced breast carcinogenesis by regulating AhR/CYP1A1 signaling pathway. Pharmacogn Mag. 13(Suppl 4):S749–S755.
   PubMedGoogle Scholar
• Hodgson E, Rose RL. 2007. Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 21(4):182–186.
   PubMed Web of Science ®Google Scholar
• Horley NJ, Beresford KJM, Chawla T, McCann GJP, Ruparelia KC, Gatchie L, Sonawane VR, Williams IS, Tan HL, Joshi P, et al. 2017. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: overcoming cisplatin resistance in CYP1B1-overexpressing lines. Eur J Med Chem. 129:159–174.
   PubMed Web of Science ®Google Scholar
• Horley NJ, Beresford KJM, Kaduskar S, Joshi P, McCann GJP, Ruparelia KC, Williams IS, Gatchie L, Sonawane VR, Bharate SB, et al. 2017. (E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent. Bioorg Med Chem Lett. 27(24):5409–5414.
   PubMed Web of Science ®Google Scholar
• Huang HJ, Chiang PH, Chen SH. 2011. Quantitative analysis of estrogens and estrogen metabolites in endogenous MCF-7 breast cancer cells by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 879(20):1748–1756.
   PubMed Web of Science ®Google Scholar
• Hummerich J, Zohm C, Pfau W. 2004. Modulation of cytochrome P450 1A1 by food-derived heterocyclic aromatic amines. Toxicology. 199(2–3):231–240.
   PubMed Web of Science ®Google Scholar
• Joshi P, Sonawane VR, Williams IS, McCann GJP, Gatchie L, Sharma R, Satti N, Chaudhuri B, Bharate SB. 2018. Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy via screening of a natural product repository. Medchemcomm. 9(2):371–382.
   PubMed Web of Science ®Google Scholar
• Kim S, Ko H, Park JE, Jung S, Lee SK, Chun YJ. 2002. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 45(1):160–164.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim SJ, Hong M, Choi HG, Kim JA, Lee S. 2016. Investigation of selective inhibitory effects of glycyrol on human CYP 1A1 and 2C9. Xenobiotica. 46(10):857–861.
   PubMed Web of Science ®Google Scholar
• Kleiner HE, Reed MJ, Digiovanni J. 2003. Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. Chem Res Toxicol. 16(3):415–422.
   PubMed Web of Science ®Google Scholar
• Kleiner HE, Vulimiri SV, Miller L, Johnson WH, Whitman CP, DiGiovanni J. 2001. Oral administration of naturally occurring coumarins leads to altered phase I and II enzyme activities and reduced DNA adduct formation by polycyclic aromatic hydrocarbons in various tissues of SENCAR mice. Carcinogenesis. 22(1):73–82.
   PubMed Web of Science ®Google Scholar
• Kleiner HE, Vulimiri SV, Reed MJ, Uberecken A, Digiovanni J. 2002. Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally ocurring furanocoumarins on skin tumor intitiation. Chem Res Toxicol. 15(2):226–235.
   PubMed Web of Science ®Google Scholar
• Koual M, Tomkiewicz C, Cano-Sancho G, Antignac JP, Bats AS, Coumoul X. 2020. Environmental chemicals, breast cancer progression and drug resistance. Environ Health. 19(1):117.
   PubMed Web of Science ®Google Scholar
• Kwon YJ, Baek HS, Ye DJ, Shin S, Kim D, Chun YJ. 2016. CYP1B1 enhances cell proliferation and metastasis through induction of EMT and activation of Wnt/beta-catenin signaling via Sp1 upregulation. PLOS One. 11(3):e0151598.
   PubMed Web of Science ®Google Scholar
• Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2003. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 23(2):165–172.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. 2003. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 144(8):3382–3398.
   PubMed Web of Science ®Google Scholar
• Lee D, Perez P, Jackson W, Chin T, Galbreath M, Fronczek FR, Isovitsch R, Iimoto DS. 2016. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1. Bioorg Med Chem Lett. 26(14):3243–3247.
   PubMed Web of Science ®Google Scholar
• Lee JE, Safe S. 2001. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol. 62(8):1113–1124.
   PubMed Web of Science ®Google Scholar
• Lemaire P, Livingstone DR. 1995. Effects of the inhibitor ellipticine on cytochrome P450-reductase and cytochrome P450 (1A) function in hepatic microsomes of flounder (Platichthys flesus). Mar Environ Res. 39(1–4):1–77.
   Web of Science ®Google Scholar
• Levin VA, Jiang X, Kagan R. 2018. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 29(5):1049–1055.
   PubMed Web of Science ®Google Scholar
• Li Y, Cui J, Jia J. 2021. The activation of procarcinogens by CYP1A1/1B1 and related chemo-preventive agents: a review. Curr Cancer Drug Targets. 21(1):21–54.
   PubMed Web of Science ®Google Scholar
• Licznerska B, Szaefer H, Wierzchowski M, Mikstacka R, Papierska K, Baer-Dubowska W. 2018. Evaluation of the effect of the new methoxy-stilbenes on expression of receptors and enzymes involved in estrogen synthesis in cancer breast cells. Mol Cell Biochem. 444(1–2):53–62.
   PubMed Web of Science ®Google Scholar
• Licznerska B, Szaefer H, Wierzchowski M, Sobierajska H, Baer-Dubowska W. 2017. Resveratrol and its methoxy derivatives modulate the expression of estrogen metabolism enzymes in breast epithelial cells by AhR down-regulation. Mol Cell Biochem. 425(1–2):169–179.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AYH. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 35(5):361–390.
   PubMed Web of Science ®Google Scholar
• Liu J, Nguyen TT, Dupart PS, Sridhar J, Zhang X, Zhu N, Stevens CL, Foroozesh M. 2012. 7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2. Chem Res Toxicol. 25(5):1047–1057.
   PubMed Web of Science ®Google Scholar
• Liu J, Sridhar J, Foroozesh M. 2013. Cytochrome P450 family 1 inhibitors and structure-activity relationships. Molecules. 18(12):14470–14495.
   PubMed Web of Science ®Google Scholar
• Liu J, Taylor SF, Dupart PS, Arnold CL, Sridhar J, Jiang Q, Wang Y, Skripnikova EV, Zhao M, Foroozesh M. 2013. Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1. J Med Chem. 56(10):4082–4092.
   PubMed Web of Science ®Google Scholar
• Lo SN, Chang YP, Tsai KC, Chang CY, Wu TS, Ueng YF. 2013. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. Toxicol Appl Pharmacol. 272(3):671–680.
   PubMed Web of Science ®Google Scholar
• Lo SN, Shen CC, Chang CY, Tsai KC, Huang CC, Wu TS, Ueng YF. 2015. The effect of oxidation on berberine-mediated CYP1 inhibition: oxidation behavior and metabolite-mediated inhibition. Drug Metab Dispos. 43(7):1100–1107.
   PubMed Web of Science ®Google Scholar
• Lo SN, Wang CW, Chen YS, Huang CC, Wu TS, Li LA, Lee IJ, Ueng YF. 2017. Berberine activates aryl hydrocarbon receptor but suppresses CYP1A1 induction through miR-21-3p stimulation in MCF-7 breast cancer cells. Molecules. 22(11):1847.
   PubMed Web of Science ®Google Scholar
• Lovekamp-Swan T, Jetten AM, Davis BJ. 2003. Dual activation of PPARα and PPARγ by mono-(2-ethylhexyl) phthalate in rat ovarian granulosa cells. Mol Cell Endocrinol. 201(1–2):133–141.
   PubMed Web of Science ®Google Scholar
• Lozan E, Shinkaruk S, Al Abed SA, Lamothe V, Potier M, Marighetto A, Schmitter JM, Bennetau-Pelissero C, Bure C. 2017. Derivatization-free LC-MS/MS method for estrogen quantification in mouse brain highlights a local metabolic regulation after oral versus subcutaneous administration. Anal Bioanal Chem. 409(22):5279–5289.
   PubMed Web of Science ®Google Scholar
• Mahemuti L, Chen Q, Coughlan MC, Qiao C, Chepelev NL, Florian M, Dong D, Woodworth RG, Yan J, Cao X-L, et al. 2018. Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 92(4):1453–1469.
   PubMed Web of Science ®Google Scholar
• Mammen JS, Kleiner HE, Digiovanni J, Sutter TR, Strickland PT. 2005. Coumarins are competitive inhibitors of cytochrome P450 1B1, with equal potency for allelic variants. Pharmacogenet Genomics. 15(3):183–188.
   PubMed Web of Science ®Google Scholar
• Mao X, Wang J, Wang Q, Yang L, Li Y, Lin H, Peng Y, Zheng J. 2019. Nitidine chloride-induced CYP1 enzyme inhibition and alteration of estradiol metabolism. Drug Metab Dispos. 47(8):919–927.
   PubMed Web of Science ®Google Scholar
• Marumoto S, Oda Y, Miyazawa M. 2011. Antigenotoxic activity of naturally occurring furanocoumarins. Environ Mol Mutagen. 52(8):646–657.
   PubMed Web of Science ®Google Scholar
• Masson LF, Sharp L, Cotton SC, Little J. 2005. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. Am J Epidemiol. 161(10):901–915.
   PubMed Web of Science ®Google Scholar
• Mense SM, Chhabra J, Bhat HK. 2008. Preferential induction of cytochrome P450 1A1 over cytochrome P450 1B1 in human breast epithelial cells following exposure to quercetin. J Steroid Biochem Mol Biol. 110(1–2):157–162.
   PubMed Web of Science ®Google Scholar
• Mikstacka R, Baer-Dubowska W, Wieczorek M, Sobiak S. 2008. Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities. Mol Nutr Food Res. 52(Suppl 1):S77–S83.
   PubMed Web of Science ®Google Scholar
• Mikstacka R, Przybylska D, Rimando AM, Baer-Dubowska W. 2007. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol Nutr Food Res. 51(5):517–524.
   PubMed Web of Science ®Google Scholar
• Mikstacka R, Rimando AM, Dutkiewicz Z, Stefański T, Sobiak S. 2012. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1. Bioorg Med Chem. 20(17):5117–5126.
   PubMed Web of Science ®Google Scholar
• Miron A, Aprotosoaie AC, Trifan A, Xiao J. 2017. Flavonoids as modulators of metabolic enzymes and drug transporters. Ann N Y Acad Sci. 1398(1):152–167.
   PubMed Web of Science ®Google Scholar
• Mohammadi-Bardbori A, Bengtsson J, Rannug U, Rannug A, Wincent E. 2012. Quercetin, resveratrol, and curcumin are indirect activators of the aryl hydrocarbon receptor (AHR). Chem Res Toxicol. 25(9):1878–1884.
   PubMed Web of Science ®Google Scholar
• MohanKumar SMJ, Balasubramanian P, Subramanian M, MohanKumar PS. 2018. Chronic estradiol exposure-harmful effects on behavior, cardiovascular and reproductive functions. Reproduction. 156(5):R169–R186.
   PubMed Web of Science ®Google Scholar
• Mohd Siddique MU, McCann GJ, Sonawane VR, Horley N, Gatchie L, Joshi P, Bharate SB, Jayaprakash V, Sinha BN, Chaudhuri B. 2017. Quinazoline derivatives as selective CYP1B1 inhibitors. Eur J Med Chem. 130:320–327.
   PubMed Web of Science ®Google Scholar
• Mondal A, Gandhi A, Fimognari C, Atanasov AG, Bishayee A. 2019. Alkaloids for cancer prevention and therapy: current progress and future perspectives. Eur J Pharmacol. 858:172472.
   PubMed Web of Science ®Google Scholar
• Monostory K, Tamási V, Vereczkey L, Perjési P. 2003. A study on CYP1A inhibitory action of E-2-(4′-methoxybenzylidene)-1-benzosuberone and some related chalcones and cyclic chalcone analogues. Toxicology. 184(2–3):203–210.
   PubMed Web of Science ®Google Scholar
• Moore SC, Matthews CE, Ou Shu X, Yu K, Gail MH, Xu X, Ji B-T, Chow W-H, Cai Q, Li H, et al. 2016. Endogenous estrogens, estrogen metabolites, and breast cancer risk in postmenopausal Chinese women. J Natl Cancer Inst. 108(10):djw103.
   PubMedGoogle Scholar
• Moyano P, Garcia J, Garcia JM, Pelayo A, Munoz-Calero P, Frejo MT, Anadon MJ, Lobo M, Del Pino J. 2020. Chlorpyrifos-induced cell proliferation in human breast cancer cell lines differentially mediated by estrogen and aryl hydrocarbon receptors and KIAA1363 enzyme after 24 h and 14 days exposure. Chemosphere. 251:126426.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H. 2007. Breast cancer: are estrogen metabolites carcinogenic? Climacteric. 10(Suppl 2):62–65.
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Ponnusankar S, Pandit S, Hazam PK, Ahmmed M, Mukherjee K. 2011. Botanicals as medicinal food and their effects on drug metabolizing enzymes. Food Chem Toxicol. 49(12):3142–3153.
   PubMed Web of Science ®Google Scholar
• Nishizawa H, Imanishi S, Manabe N. 2005. Effects of exposure in utero to bisphenol A on the expression of aryl hydrocarbon receptor, related factors, and xenobiotic metabolizing enzymes in murine embryos. J Reprod Dev. 51(5):593–605.
   PubMed Web of Science ®Google Scholar
• Niwa T, Murayama N, Imagawa Y, Yamazaki H. 2015. Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 47(2):89–110.
   PubMed Web of Science ®Google Scholar
• O'Brien PJ, Chan K, Silber PM. 2004. Human and animal hepatocytes in vitro with extrapolation in vivo. Chem Biol Interact. 150(1):97–114.
   PubMed Web of Science ®Google Scholar
• Pastorková B, Vrzalová A, Bachleda P, Dvořák Z. 2017. Hydroxystilbenes and methoxystilbenes activate human aryl hydrocarbon receptor and induce CYP1A genes in human hepatoma cells and human hepatocytes. Food Chem Toxicol. 103:122–132.
   PubMed Web of Science ®Google Scholar
• Peyrat JF, Brion JD, Alami M. 2012. Synthetic 2-methoxyestradiol derivatives: structure-activity relationships. CMC. 19(24):4142–4156.
   Web of Science ®Google Scholar
• Piotrowska H, Myszkowski K, Ziółkowska A, Kulcenty K, Wierzchowski M, Kaczmarek M, Murias M, Kwiatkowska-Borowczyk E, Jodynis-Liebert J. 2012. Resveratrol analogue 3,4,4′,5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol. 263(1):53–60.
   PubMed Web of Science ®Google Scholar
• Piver B, Berthou F, Dreano Y, Lucas D. 2003. Differential inhibition of human cytochrome P450 enzymes by ε-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci. 73(9):1199–1213.
   PubMed Web of Science ®Google Scholar
• Prateeksha Yusuf MA, Singh BN, Sudheer S, Kharwar RN, Siddiqui S, Abdel-Azeem AM, Fernandes Fraceto L, Dashora K, Gupta, VK. 2019. Chrysophanol: a natural anthraquinone with multifaceted biotherapeutic potential. Biomolecules. 9(2):68.
   PubMed Web of Science ®Google Scholar
• Ramirez-Rosas MB, Cobos-Puc LE, Sanchez LA, Gutierrez-Lara EJ, Centurion D. 2014. Pharmacological characterization of the mechanisms involved in the vasorelaxation induced by progesterone and 17beta-estradiol on isolated canine basilar and internal carotid arteries. Steroids. 89:33–40.
   PubMed Web of Science ®Google Scholar
• Ramsden D, Perloff ES, Whitcher-Johnstone A, Ho T, Patel R, Kozminski KD, Fullenwider CL, Zhang JG. 2022. Predictive in vitro-in vivo extrapolation for time dependent inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 using pooled human hepatocytes, human liver microsomes, and a simple mechanistic static model. Drug Metab Dispos. 50(2):114–127.
   PubMed Web of Science ®Google Scholar
• Rendic S, Guengerich FP. 2012. Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol. 25(7):1316–1383.
   PubMed Web of Science ®Google Scholar
• Rodgers KM, Udesky JO, Rudel RA, Brody JG. 2018. Environmental chemicals and breast cancer: an updated review of epidemiological literature informed by biological mechanisms. Environ Res. 160:152–182.
   PubMed Web of Science ®Google Scholar
• Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW, Higginbotham SM, Cavalieri EL. 2003. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis. 24(4):697–702.
   PubMed Web of Science ®Google Scholar
• Sæther S, Bakken K, Lund E. 2012. The risk of breast cancer linked to menopausal hormone therapy. Tidsskr nor Laegeforen. 132(11):1330–1334.
   PubMedGoogle Scholar
• Sahab-Negah S, Hajali V, Moradi HR, Gorji A. 2020. The impact of estradiol on neurogenesis and cognitive functions in Alzheimer’s disease. Cell Mol Neurobiol. 40(3):283–299.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Wang JP. 2015. Estrogen metabolites and breast cancer. Steroids. 99(Pt A):61–66.
   PubMed Web of Science ®Google Scholar
• Santes-Palacios R, Marroquin-Perez AL, Hernandez-Ojeda SL, Camacho-Carranza R, Govezensky T, Espinosa-Aguirre JJ. 2020. Human CYP1A1 inhibition by flavonoids. Toxicol In Vitro. 62:104681.
   PubMed Web of Science ®Google Scholar
• Santes-Palacios R, Romo-Mancillas A, Camacho-Carranza R, Espinosa-Aguirre JJ. 2016. Inhibition of human and rat CYP1A1 enzyme by grapefruit juice compounds. Toxicol Lett. 258:267–275.
   PubMed Web of Science ®Google Scholar
• Schwarz D, Kisselev P, Schunck WH, Roots I. 2011. Inhibition of 17beta-estradiol activation by CYP1A1: genotype- and regioselective inhibition by St. John’s Wort and several natural polyphenols. Biochim Biophys Acta. 1814(1):168–174.
   PubMed Web of Science ®Google Scholar
• Sekimoto M, Sumi H, Hosaka T, Umemura T, Nishikawa A, Degawa M. 2016. Aryl hydrocarbon receptor activation and CYP1A induction by cooked food-derived carcinogenic heterocyclic amines in human HepG2 cell lines. Food Chem Toxicol. 97:256–264.
   PubMed Web of Science ®Google Scholar
• Sharma R, Williams IS, Gatchie L, Sonawane VR, Chaudhuri B, Bharate SB. 2018a. Furanoflavones pongapin and lanceolatin B blocks the cell cycle and induce senescence in CYP1A1-overexpressing breast cancer cells. Bioorg Med Chem. 26(23–24):6076–6086.
   PubMed Web of Science ®Google Scholar
• Sharma R, Williams IS, Gatchie L, Sonawane VR, Chaudhuri B, Bharate SB. 2018b. Khellinoflavanone, a semisynthetic derivative of khellin, overcomes benzo[a]pyrene toxicity in human normal and cancer cells that express CYP1A1. ACS Omega. 3(8):8553–8566.
   PubMed Web of Science ®Google Scholar
• Shimada T, Inoue K, Suzuki Y, Kawai T, Azuma E, Nakajima T, Shindo M, Kurose K, Sugie A, Yamagishi Y, et al. 2002. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis. 23(7):1199–1207.
   PubMed Web of Science ®Google Scholar
• Shimada T, Tanaka K, Takenaka S, Murayama N, Martin MV, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M. 2010. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol. 23(12):1921–1935.
   PubMed Web of Science ®Google Scholar
• Singh NP, Singh US, Nagarkatti M, Nagarkatti PS. 2011. Resveratrol (3,5,4′-trihydroxystilbene) protects pregnant mother and fetus from the immunotoxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol Nutr Food Res. 55(2):209–219.
   PubMed Web of Science ®Google Scholar
• Sonawane VR, Siddique MUM, Gatchie L, Williams IS, Bharate SB, Jayaprakash V, Sinha BN, Chaudhuri B. 2019. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance. Eur J Pharm Sci. 131:177–194.
   PubMed Web of Science ®Google Scholar
• Song X, Dong G, Zhou Y. 2019. In vitro inhibitory effects of isofraxidin on human liver cytochrome P450 enzymes. Pharmacology. 103(3–4):120–127.
   PubMed Web of Science ®Google Scholar
• Spink DC, Wu SJ, Spink BC, Hussain MM, Vakharia DD, Pentecost BT, Kaminsky LS. 2008. Induction of CYP1A1 and CYP1B1 by benzo(k)fluoranthene and benzo(a)pyrene in T-47D human breast cancer cells: roles of PAH interactions and PAH metabolites. Toxicol Appl Pharmacol. 226(3):213–224.
   PubMed Web of Science ®Google Scholar
• Sridhar J, Ellis J, Dupart P, Liu J, Stevens CL, Foroozesh M. 2012. Development of flavone propargyl ethers as potent and selective inhibitors of cytochrome P450 enzymes 1A1 and 1A2. Drug Metab Lett. 6(4):275–284.
   PubMedGoogle Scholar
• Sridhar J, Liu J, Foroozesh M, Klein Stevens CL. 2012. Inhibition of cytochrome p450 enzymes by quinones and anthraquinones. Chem Res Toxicol. 25(2):357–365.
   PubMed Web of Science ®Google Scholar
• Sridhar J, Liu J, Komati R, Schroeder R, Jiang Q, Tram P, Riley K, Foroozesh M. 2017. Ortho-methylarylamines as time-dependent inhibitors of cytochrome P450 1A1 enzyme. Drug Metab Lett. 10(4):270–277.
   PubMedGoogle Scholar
• Sun D, Sakakibara H, Ashida H, Danno G, Kanazawa K. 2000. Cytochrome P4501A1-inhibitory action of antimutagenic anthraquinones in medicinal plants and the structure-activity relationship. Biosci Biotechnol Biochem. 64(7):1373–1378.
   PubMed Web of Science ®Google Scholar
• Surichan S, Androutsopoulos VP, Sifakis S, Koutala E, Tsatsakis A, Arroo RR, Boarder MR. 2012. Bioactivation of the citrus flavonoid nobiletin by CYP1 enzymes in MCF7 breast adenocarcinoma cells. Food Chem Toxicol. 50(9):3320–3328.
   PubMed Web of Science ®Google Scholar
• Surichan S, Arroo RR, Tsatsakis AM, Androutsopoulos VP. 2018. Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1-mediated metabolism to the product 4′ hydroxy tangeretin. Toxicol In Vitro. 50:274–284.
   PubMed Web of Science ®Google Scholar
• Takahashi E, Fujita KI, Kamataki T, Arimoto-Kobayashi S, Okamoto K, Negishi T. 2002. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin. Mutat Res. 508(1–2):147–156.
   PubMed Web of Science ®Google Scholar
• Takemura H, Itoh T, Yamamoto K, Sakakibara H, Shimoi K. 2010. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 18(17):6310–6315.
   PubMed Web of Science ®Google Scholar
• Takemura H, Nagayoshi H, Matsuda T, Sakakibara H, Morita M, Matsui A, Ohura T, Shimoi K. 2010. Inhibitory effects of chrysoeriol on DNA adduct formation with benzo[a]pyrene in MCF-7 breast cancer cells. Toxicology. 274(1–3):42–48.
   PubMed Web of Science ®Google Scholar
• Takemura H, Uchiyama H, Ohura T, Sakakibara H, Kuruto R, Amagai T, Shimoi K. 2010. A methoxyflavonoid, chrysoeriol, selectively inhibits the formation of a carcinogenic estrogen metabolite in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 118(1–2):70–76.
   PubMed Web of Science ®Google Scholar
• Tian KM, Li JJ, Xu SW. 2019. Rutaecarpine: a promising cardiovascular protective alkaloid from Evodia rutaecarpa (Wu Zhu Yu). Pharmacol Res. 141:541–550.
   PubMed Web of Science ®Google Scholar
• Tian W, Wang C, Li D, Hou H. 2020. Novel anthraquinone compounds as anticancer agents and their potential mechanism. Future Med Chem. 12(7):627–644.
   PubMed Web of Science ®Google Scholar
• Tschiffely AE, Schuh RA, Prokai-Tatrai K, Prokai L, Ottinger MA. 2016. A comparative evaluation of treatments with 17beta-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer’s disease. Horm Behav. 83:39–44.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Nakajima M, Yokoi T. 2005. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 227(2):115–124.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Chen CC, Yamazaki H, Kiyotani K, Chang YP, Lo WS, Li DT, Tsai PL. 2013. Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. Drug Metab Pharmacokinet. 28(3):229–238.
   PubMed Web of Science ®Google Scholar
• Ueng Y-F, Jan W-C, Lin L-C, Chen T-L, Guengerich FP, Chen C-F. 2002. The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. Drug Metab Dispos. 30(3):349–353.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Wang JJ, Lin LC, Park SS, Chen CF. 2001. Induction of cytochrome P450-dependent monooxygenase in mouse liver and kidney by rutaecarpine, an alkaloid of the herbal drug Evodia rutaecarpa. Life Sci. 70(2):207–217.
   PubMed Web of Science ®Google Scholar
• van den Brand AD, Villevoye J, Nijmeijer SM, van den Berg M, van Duursen MBM. 2019. Anti-tumor properties of methoxylated analogues of resveratrol in malignant MCF-7 but not in non-tumorigenic MCF-10A mammary epithelial cell lines. Toxicology. 422:35–43.
   PubMed Web of Science ®Google Scholar
• van Duursen MBM, Sanderson JT, van der Bruggen M, van der Linden J, van den Berg M. 2003. Effects of several dioxin-like compounds on estrogen metabolism in the malignant MCF-7 and nontumorigenic MCF-10A human mammary epithelial cell lines. Toxicol Appl Pharmacol. 190(3):241–250.
   PubMed Web of Science ®Google Scholar
• Vrba J, Kosina P, Ulrichova J, Modriansky M. 2004. Involvement of cytochrome P450 1A in sanguinarine detoxication. Toxicol Lett. 151(2):375–387.
   PubMed Web of Science ®Google Scholar
• Wang C, Huo X, Tian X, Xu M, Dong P, Luan Z, Wang X, Zhang B, Zhang B, Huang S, et al. 2016. Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model. Br J Pharmacol. 173(22):3261–3275.
   PubMed Web of Science ®Google Scholar
• Wang S, Dunlap TL, Howell CE, Mbachu OC, Rue EA, Phansalkar R, Chen SN, Pauli GF, Dietz BM, Bolton JL. 2016. Hop (Humulus lupulus L.) extract and 6-prenylnaringenin induce P450 1A1 catalyzed estrogen 2-hydroxylation. Chem Res Toxicol. 29(7):1142–1150.
   PubMed Web of Science ®Google Scholar
• Wen CJ, Wu LX, Fu LJ, Shen DY, Zhang X, Zhang YW, Yu J, Zhou HH. 2014. Preferential induction of CYP1A1 over CYP1B1 in human breast cancer MCF-7 cells after exposure to berberine. Asian Pac J Cancer Prev. 15(1):495–499.
   PubMedGoogle Scholar
• Wen X, Walle UK, Walle T. 2005. 5,7-Dimethoxyflavone downregulates CYP1A1 expression and benzo[a]pyrene-induced DNA binding in HepG2 cells. Carcinogenesis. 26(4):803–809.
   PubMed Web of Science ®Google Scholar
• Wierzchowski M, Dutkiewicz Z, Gielara-Korzańska A, Korzański A, Teubert A, Teżyk A, Stefański T, Baer-Dubowska W, Mikstacka R. 2017. Synthesis, biological evaluation and docking studies of trans-stilbene methylthio derivatives as cytochromes P450 family 1 inhibitors. Chem Biol Drug Des. 90(6):1226–1236.
   PubMed Web of Science ®Google Scholar
• Williams IS, Joshi P, Gatchie L, Sharma M, Satti NK, Vishwakarma RA, Chaudhuri B, Bharate SB. 2017. Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance. Bioorg Med Chem Lett. 27(16):3683–3687.
   PubMed Web of Science ®Google Scholar
• Wójtowicz AK, Honkisz E, Zięba-Przybylska D, Milewicz T, Kajta M. 2011. Effects of two isomers of DDT and their metabolite DDE on CYP1A1 and AhR function in human placental cells. Pharmacol Rep. 63(6):1460–1468.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhang X, Ye Y, Li X. 2019. Bisphenol A affects estradiol metabolism by targeting CYP1A1 and CYP19A1 in human placental JEG-3 cells. Toxicol In Vitro. 61:104615.
   PubMed Web of Science ®Google Scholar
• Yager JD. 2015. Mechanisms of estrogen carcinogenesis: the role of E2/E1-quinone metabolites suggests new approaches to preventive intervention–a review. Steroids. 99(Pt A):56–60.
   PubMed Web of Science ®Google Scholar
• Yu H, Balani SK, Chen W, Cui D, He L, Humphreys WG, Mao J, Lai WG, Lee AJ, Lim H-K, et al. 2015. Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group. Drug Metab Dispos. 43(4):620–630.
   PubMed Web of Science ®Google Scholar
• Yue W, Santen RJ, Wang J-P, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, et al. 2003. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol. 86(3–5):477–486.
   PubMed Web of Science ®Google Scholar
• Yue W, Yager JD, Wang JP, Jupe ER, Santen RJ. 2013. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids. 78(2):161–170.
   PubMed Web of Science ®Google Scholar
• Zahid M, Mondal B, LeVan TD, Rogan EG. 2019. Estrogen metabolism in African-American women with and without breast cancer: a pilot study. Chem Res Toxicol. 32(1):190–194.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Zdarilova A, Vrzal R, Rypka M, Ulrichova J, Dvorak Z. 2006. Investigation of sanguinarine and chelerythrine effects on CYP1A1 expression and activity in human hepatoma cells. Food Chem Toxicol. 44(2):242–249.
   PubMed Web of Science ®Google Scholar
• Zha C, Xiao H, Song B, Zheng C, Yang X, Wang W, Wang L. 2021. Resveratrol promotes mammary cell proliferation and antioxidation capacity during pregnancy and lactation in mice. J Appl Microbiol. 130(2):450–463.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wang J, Sheng A, Huang S, Tang Y, Ma S, Hong G. 2020. Emodin inhibits the proliferation of MCF-7 human breast cancer cells through activation of aryl hydrocarbon receptor (AhR). Front Pharmacol. 11:622046.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lin J, Talukder M, Zhu SY, Li MZ, Wang HR, Li JL. 2020. Aryl hydrocarbon receptor as a target for lycopene preventing DEHP-induced spermatogenic disorders. J Agric Food Chem. 68(15):4355–4366.
   PubMed Web of Science ®Google Scholar
• Zhu BT, Lee AJ. 2005. NADPH-dependent metabolism of 17beta-estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms. Steroids. 70(4):225–244.
   PubMed Web of Science ®Google Scholar
• Ziegler RG, Fuhrman BJ, Moore SC, Matthews CE. 2015. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids. 99(Pt A):67–75.
   PubMed Web of Science ®Google Scholar
• Zou QY, Hong SL, Kang HY, Ke X, Wang XQ, Li J, Shen Y. 2020. Effect of di-(2-ethylhexyl) phthalate (DEHP) on allergic rhinitis. Sci Rep. 10(1):14625.
   PubMed Web of Science ®Google Scholar